Kyverna Therapeutics, Inc. (KYTX) stock
KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.70−0.06 (-1.26%)
Close on Nov 17, 2026Market cap $290.66MP/E –Yield –
Kyverna Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Kyverna Therapeutics's total debt was $24.96M at Sep 30, 2026. For fiscal 2025 it was $24.74M.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.74M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $24.96M | – |
| Q2 FY2026 | Jun 30, 2026 | $24.88M | – |
| Q4 FY2025 | Dec 31, 2025 | $24.74M | – |
See a number that looks wrong?